PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Study to Evaluate the Effect of Repeat-Dose Rifampin on the Pharmacokinetics (PK) of PF-06651600
- First Posted Date
- 2020-02-12
- Last Posted Date
- 2020-09-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT04266509
- Locations
- 🇧🇪
Brussels Clinical Research Unit, Brussels, Bruxelles-capitale, Région DE, Belgium
A Study To Compare The Effectiveness Of Tofacitinib 11 Mg Once A Day To Tofacitinib 5 Mg Twice A Day
- Conditions
- Arthritis Rheumatoid
- First Posted Date
- 2020-02-12
- Last Posted Date
- 2023-05-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 298
- Registration Number
- NCT04267380
- Locations
- 🇺🇸
Pfizer, New York, New York, United States
Renal Impairment Study of PF-06700841
- First Posted Date
- 2020-02-07
- Last Posted Date
- 2024-01-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 30
- Registration Number
- NCT04260464
- Locations
- 🇺🇸
Investigational Drug Services (IDS) University of Miami Hospitals and Clinics, Research Pharmacy, Miami, Florida, United States
🇺🇸University of Miami Division of Clinical Pharmacology, Miami, Florida, United States
🇺🇸Prism Research LLC dba Nucleus Network, Saint Paul, Minnesota, United States
A TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A BOOSTER DOSE OF A GROUP B STREPTOCOCCUS 6 VALENT POLYSACCHARIDE CONJUGATE VACCINE (GBS6) IN HEALTHY ADULTS
- Conditions
- Group B Streptococcal Infections
- Interventions
- Biological: Group B streptoccous 6-valent polysaccharide conjugate vaccine (GBS6)
- First Posted Date
- 2020-02-06
- Last Posted Date
- 2021-10-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 151
- Registration Number
- NCT04258995
- Locations
- 🇺🇸
Clinical Research Atlanta, Stockbridge, Georgia, United States
🇺🇸Kentucky Pediatric & Adult Research Inc., Bardstown, Kentucky, United States
🇺🇸J. Lewis Research, Inc./ Foothill Family Clinic South, Salt Lake City, Utah, United States
A Drug-Drug Interaction Study To Estimate The Effect Of Tafamidis On Rosuvastatin Pharmacokinetics
- First Posted Date
- 2020-02-05
- Last Posted Date
- 2020-09-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT04253353
- Locations
- 🇧🇪
Brussels Clinical Research Unit, Brussels, Bruxelles-capitale, Région DE, Belgium
Dose Escalation Study of PF-07209326 in Healthy Participants and Participants With Sickle Cell Disease
- Conditions
- HealthySickle Cell Anemia
- Interventions
- Biological: PF-07209326Biological: Placebo
- First Posted Date
- 2020-02-05
- Last Posted Date
- 2023-12-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 52
- Registration Number
- NCT04255875
- Locations
- 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States
🇺🇸Howard University College of Medicine, Washington, District of Columbia, United States
🇺🇸Golisano Children's Hospital of Southwest Florida, Fort Myers, Florida, United States
A Low Interventional Study to Monitor Activity Using Wearable Sensors in Duchenne Muscular Dystrophy
- Conditions
- Duchenne Muscular Dystrophy (DMD)
- Interventions
- Device: Activity Monitor
- First Posted Date
- 2020-02-05
- Last Posted Date
- 2021-10-15
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 2
- Registration Number
- NCT04254172
- Locations
- 🇺🇸
Nationwide Children's Hospital, Columbus, Ohio, United States
Dose Escalation Study to Evaluate the Safety, Tolerability, PK and PD of Voxelotor in Patients With SCD
- First Posted Date
- 2020-01-30
- Last Posted Date
- 2023-11-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 6
- Registration Number
- NCT04247594
- Locations
- 🇬🇧
Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom
🇬🇧Guy's Hospital, London, United Kingdom
🇬🇧Hammersmith Hospital, London, United Kingdom
Safety and Efficacy of Dexmedetomidine (DEX) for Sedation of Subjects ≥1 Month to <17 Years Undergoing MRI Scans
- First Posted Date
- 2020-01-23
- Last Posted Date
- 2022-11-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 128
- Registration Number
- NCT04237792
- Locations
- 🇺🇸
Arkansas Children's, Little Rock, Arkansas, United States
🇺🇸Lucile Packard Children's Hospital, Stanford, Palo Alto, California, United States
🇺🇸University of California Davis Medical Center, Sacramento, California, United States
Patient Characteristics, Treatment Patterns And Incidence Of Events (Discontinuation, Persistence, Key Primary Clinical Outcomes) In NVAF Patients Initiating OAC Therapy In Colombia
- Conditions
- Atrial Fibrillation
- First Posted Date
- 2020-01-21
- Last Posted Date
- 2025-02-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 2076
- Registration Number
- NCT04234698
- Locations
- 🇨🇴
Pfizer Investigational Site, Bogota, Cundinamarca, Colombia